Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. Martinez-Monleon A, Oberg H, Gaarder J, Berbegall A, Javanmardi N, Djos A, Ussowicz M, Taschner-Mandl S, Ambros I, Ora I, Sandstedt B, Beiske K, Ladenstein R, Noguera R, Ambros P, Murkes L, Ljungman G, Kogner P, Fransson S, Martinsson T. Scientific Reports. 2022 Jul 20;12(1):12420. doi: 10.1038/s41598-022-16455-1. PMID: 35859155

Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. Sonzini G, Granados-Aparici S, Sanegre S, Diaz-Lagares A, Diaz-Martin J, de Andrea C, Eritja N, Bao-Caamano A, Costa-Fraga N, Garcia-Ros D, Salguero-Aranda C, Davidson B, Lopez-Lopez R, Melero I, Navarro S, Ramon Y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Frontiers in Cell and Developmental Biology. 2022 Nov 18;10:1052098. doi: 10.3389/fcell.2022.1052098. PMID: 36467415

The complexity of cancer immunotherapy illustrated through skin tumors. Vieco-Marti I, Lopez-Carrasco A, de la Cruz-Merino L, Noguera R, Alvaro Naranjo T. International Journal of Biological Markers. 2022 Jun;37(2):113-122. doi: 10.1177/03936155221088884. PMID: 35473449

Vitronectin-based hydrogels recapitulate neuroblastoma growth conditions. Monferrer E, Dobre O, Trujillo S, Oliva M, Trubert-Paneli A, Acevedo-Leon D, Noguera R, Salmeron-Sanchez M. Frontiers in Cell and Developmental Biology. 2022 Oct 11;10:988699. doi: 10.3389/fcell.2022.988699. PMID: 36425532

A G316A polymorphism in the ornithine decarboxylase gene promoter modulates mycn-driven childhood neuroblastoma. Gamble L, Purgato S, Henderson M, Di Giacomo S, Russell A, Pigini P, Murray J, Valli E, Milazzo G, Giorgi F, Cowley M, Ashton L, Bhalshankar J, Schleiermacher G, Rihani A, Van Maerken T, Vandesompele J, Speleman F, Versteeg R, Koster J, Eggert A, Noguera R, Stallings R, Tonini G, Fong K, Vaksman Z, Diskin S, Maris J, London W, Marshall G, Ziegler D, Hogarty M, Perini G, Norris M, Haber M. Cancers. 2021 Apr 9;13(8):1807. doi: 10.3390/cancers13081807. PMID: 33918978

Characterizing the invasive tumor front of aggressive uterine adenocarcinoma and leiomyosarcoma. Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares A, Jacome MA, Salguero-Aranda C, Garcia Ros D, Davidson B, Lopez R, Melero I, Navarro S, Ramon y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Frontiers in Cell and Developmental Biology. 2021 Jun 3;9:670185. doi: 10.3389/fcell.2021.670185. PMID: 34150764

Frequency and prognostic impact of alk amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Bellini A, Potschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clement N, Combaret V, Font de Mora J, George SL, Jimenez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Muhlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Journal of Clinical Oncology. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. PMID: 34115544

Immunometabolism modulation in therapy. Monferrer E, Sanegre S, Vieco-Marti I, Lopez-Carrasco A, Farinas F, Villatoro A, Abanades S, Manes S, de la Cruz-merino L, Noguera R, Naranjo T. Biomedicines. 2021 Jul 9;9(7):798. doi: 10.3390/biomedicines9070798. PMID: 34356862

Integrated CGH/WES analyses advance understanding of aggressive neuroblastoma evolution: a case study. Corallo D, Zanon C, Pantile M, Tonini G, Zin A, Francescato S, Rossi B, Trevisson E, Pinato C, Monferrer E, Noguera R, Alino S, Herrero M, Biffi A, Viscardi E, Aveic S. Cells. 2021 Oct 9;10(10):2695. doi: 10.3390/cells10102695. PMID: 34685674